Geron Stock Today
| GERN Stock | USD 1.54 0.17 12.41% |
PerformanceFair
| Odds Of DistressSmall
|
Geron is selling at 1.54 as of the 2nd of February 2026; that is 12.41% increase since the beginning of the trading day. The stock's open price was 1.37. Geron has about a 37 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 4th of November 2025 and ending today, the 2nd of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of June 1996 | Category Healthcare | Classification Health Care |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. The company was incorporated in 1990 and is headquartered in Foster City, California. The company has 638.36 M outstanding shares of which 70.45 M shares are currently shorted by private and institutional investors with about 9.04 trading days to cover. More on Geron
Moving against Geron Stock
Geron Stock Highlights
| President CEO | Harout Semerjian | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsGeron utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into Geron's leverage profile, showing how much of Geron's resources are funded through borrowing.
| ||||||||||||||||||||||||||||||||||||||||||||||
Geron (GERN) is traded on NASDAQ Exchange in USA and employs 229 people. Geron is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 874.55 M. Geron conducts business under Biotechnology sector and is part of Health Care industry. The entity has 638.36 M outstanding shares of which 70.45 M shares are currently shorted by private and institutional investors with about 9.04 trading days to cover.
Geron currently holds about 219.29 M in cash with (218.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.58.
Check Geron Probability Of Bankruptcy
Ownership AllocationGeron has a total of 638.36 Million outstanding shares. The majority of Geron outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Geron to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Geron. Please pay attention to any change in the institutional holdings of Geron as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Geron Ownership Details
Geron Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Citadel Advisors Llc | 2025-06-30 | 12 M | |
| Ubs Group Ag | 2025-06-30 | 11.7 M | |
| Goldman Sachs Group Inc | 2025-06-30 | 9.8 M | |
| Point72 Asset Management, L.p. | 2025-06-30 | 9.6 M | |
| Woodline Partners Lp | 2025-06-30 | 8 M | |
| Eversept Partners, Llc | 2025-06-30 | 7.3 M | |
| Segall Bryant & Hamill | 2025-06-30 | 7.2 M | |
| Aberdeen Group Plc | 2025-06-30 | 7 M | |
| Stempoint Capital Lp | 2025-06-30 | 6.6 M | |
| Ra Capital Management, Llc | 2025-06-30 | 60.4 M | |
| Blackrock Inc | 2025-06-30 | 50 M |
Geron Historical Income Statement
Geron Stock Against Markets
Geron Corporate Management
| Andrew Grethlein | Executive VP of Devel. and Technical Operations | Profile | |
| Faye MD | Executive Officer | Profile | |
| Joseph MD | Executive Development | Profile | |
| Dawn CFA | Senior Affairs | Profile | |
| Stephen JD | Chief VP | Profile | |
| Shanthakumar Tyavanagimatt | Senior Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Geron. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in poverty. To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Will Biotechnology sector continue expanding? Could Geron diversify its offerings? Factors like these will boost the valuation of Geron. Market participants price Geron higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Geron data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.12) | Revenue Per Share | Quarterly Revenue Growth 0.671 | Return On Assets | Return On Equity |
Understanding Geron requires distinguishing between market price and book value, where the latter reflects Geron's accounting equity. The concept of intrinsic value—what Geron's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Geron's price substantially above or below its fundamental value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Geron's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.